These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 12780556)
41. Kidney transplant in highly sensitized patients after desensitization with plasmapheresis and low-dose intravenous immunoglobulin. Yuan XP; Wang CX; Gao W; Fu Q; He XS Exp Clin Transplant; 2010 Jun; 8(2):130-5. PubMed ID: 20565369 [TBL] [Abstract][Full Text] [Related]
42. The Pre-Transplant Drop in Panel-Reactive Antibodies Titer Evaluated Using Complement-Dependent Cytotoxicity (PRA-CDC) and the Risk of Early Acute Rejection in Sensitized Kidney Transplant Recipients. Kolonko A; Bzoma B; Giza P; Styrc B; Sobolewski M; Chudek J; Dębska-Ślizień A; Więcek A Medicina (Kaunas); 2018 Sep; 54(5):. PubMed ID: 30344297 [No Abstract] [Full Text] [Related]
43. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Jordan SC; Vo A; Bunnapradist S; Toyoda M; Peng A; Puliyanda D; Kamil E; Tyan D Transplantation; 2003 Aug; 76(4):631-6. PubMed ID: 12973100 [TBL] [Abstract][Full Text] [Related]
44. Plasmapheresis, intravenous cytomegalovirus-specific immunoglobulin and reversal of antibody-mediated rejection in a pediatric renal transplant recipient: a case report. Furth S; Neu AM; Hart J; Zachary A; Colombani P; Fivush BA Pediatr Transplant; 1999 May; 3(2):146-9. PubMed ID: 10389137 [TBL] [Abstract][Full Text] [Related]
45. Intravenous immunoglobulins and kidney transplantation in patients with anti-HLA antibodies. Glotz D; Antoine C; Haymann JP; Julia P; Duboust A; Bariéty J Adv Nephrol Necker Hosp; 2000; 30():221-33. PubMed ID: 11068645 [No Abstract] [Full Text] [Related]
46. HLA Class Ia and Ib Polyreactive Anti-HLA-E IgG2a Monoclonal Antibodies (TFL-006 and TFL-007) Suppress Anti-HLA IgG Production by CD19+ B Cells and Proliferation of CD4+ T Cells While Upregulating Tregs. Ravindranath MH J Immunol Res; 2017; 2017():3475926. PubMed ID: 28634589 [TBL] [Abstract][Full Text] [Related]
47. Proposed relationship between intravenous immunoglobulin and thrombosis in renal transplant recipients. Duronio A; Bajjoka I; Hsaiky L; Parasuraman R Ann Pharmacother; 2007 Feb; 41(2):354-8. PubMed ID: 17264157 [TBL] [Abstract][Full Text] [Related]
48. Induction of PD-L1 on monocytes: a new mechanism by which IVIg inhibits mixed lymphocyte reactions. Padet L; Loubaki L; Bazin R Immunobiology; 2014 Sep; 219(9):687-94. PubMed ID: 24875729 [TBL] [Abstract][Full Text] [Related]
49. Blockade of proliferation and tumor necrosis factor-alpha production occurring during mixed lymphocyte reaction by interferon-gamma-specific natural antibodies contained in intravenous immunoglobulins. Toungouz M; Denys C; Dupont E Transplantation; 1996 Nov; 62(9):1292-6. PubMed ID: 8932274 [TBL] [Abstract][Full Text] [Related]
50. Kinetics of cellular and humoral immunity in a successful case of positive crossmatch kidney transplantation: a case report. Tanimine N; Ide K; Yamashita M; Tanaka Y; Igarashi Y; Banshodani M; Tazawa H; Basnet NB; Doskali M; Onoe T; Tashiro H; Ohdan H Transplant Proc; 2011; 43(6):2411-4. PubMed ID: 21839279 [TBL] [Abstract][Full Text] [Related]
51. Intravenous immunoglobulin, HLA allele typing and HLAMatchmaker facilitate successful transplantation in highly sensitized pediatric renal allograft recipients. Valentini RP; Nehlsen-Cannarella SL; Gruber SA; Mattoo TK; West MS; Lang C; Imam AA Pediatr Transplant; 2007 Feb; 11(1):77-81. PubMed ID: 17239127 [TBL] [Abstract][Full Text] [Related]
52. Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg). A potential tool for transplantation of immunized patients. Glotz D; Haymann JP; Sansonetti N; Francois A; Menoyo-Calonge V; Bariety J; Druet P Transplantation; 1993 Aug; 56(2):335-7. PubMed ID: 8356587 [TBL] [Abstract][Full Text] [Related]
53. Analysis of anti-HLA antibodies in sensitized kidney transplant candidates subjected to desensitization with intravenous immunoglobulin and rituximab. Lobashevsky AL; Higgins NG; Rosner KM; Mujtaba MA; Goggins WC; Taber TE Transplantation; 2013 Jul; 96(2):182-90. PubMed ID: 23778648 [TBL] [Abstract][Full Text] [Related]
55. Use of high-dose human intravenous immunoglobulin therapy in sensitized patients awaiting transplantation: the Cedars-Sinai experience. Jordan SC; Vo AA; Nast CC; Tyan D Clin Transpl; 2003; ():193-8. PubMed ID: 15387111 [TBL] [Abstract][Full Text] [Related]
56. [HLA-incompatibility and kidney transplant: a question of desensitization]. Grosjean F G Ital Nefrol; 2011; 28(6):581. PubMed ID: 22167608 [No Abstract] [Full Text] [Related]
57. The effectiveness of the combination of rituximab and high-dose immunoglobulin in the immunomodulation of sensitized kidney transplant candidates. Taber T; Mujtaba MA; Goggins W; Higgins N; Sharfuddin A; Yaqub MS; Mishler D; Book B; Chen J; Lobashevsky A Clin Transplant; 2013; 27(4):E375-82. PubMed ID: 23721524 [TBL] [Abstract][Full Text] [Related]
58. 7th International Immunoglobulin Conference: Transplantation. Jordan SC; Glotz D Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):46-7. PubMed ID: 25546758 [TBL] [Abstract][Full Text] [Related]
59. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Montgomery RA; Zachary AA; Racusen LC; Leffell MS; King KE; Burdick J; Maley WR; Ratner LE Transplantation; 2000 Sep; 70(6):887-95. PubMed ID: 11014642 [TBL] [Abstract][Full Text] [Related]